NOVO NORDISK A/S
the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Name | Jesper Brandgaard |
Reason for reporting | Chief Financial Officer |
Financial instrument and ID code | Novo Nordisk B DK0060534915 |
Type of transaction | Sale of shares |
Date of transaction | 30 October 2014 |
Place of transaction | Nasdaq Copenhagen |
Volume of transaction | 22,000 shares |
Total value of transaction | DKK 5,870,216 |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Company announcement No 65 / 2014
Page 2 of 4
Name | Mads Krogsgaard Thomsen |
Reason for reporting | Chief Science Officer |
Financial instrument and ID code | Novo Nordisk B DK0060534915 |
Type of transaction | Purchase of shares |
Date of transaction | 30 October 2014 |
Place of transaction | Nasdaq Copenhagen |
Volume of transaction | 1,250 shares |
Total value of transaction | DKK 325,250 |
Publication shall take place no later than two working days after the trading by board members or executives or notification of trading by associated persons. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached
5,000 euros.
Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)-3), or to which a board
member/executive and/or a person mentioned in 1)-3) has managerial responsibilities or economic interests substantially equivalent to the legal person.
Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.
Novo Nordisk A/SInvestor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Company announcement No 65 / 2014
Page 3 of 4
What is financial instrument and ID code?Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US- based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.
What is date and place of transaction?Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie Nasdaq Copenhagen or New York Stock Exchange.
What is volume and value of transaction?The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately
40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's
B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.
Further information Media: Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
Investors: Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen
Melanie Raouzeos
+45 3079 6376
+45 3075 3479
dabo@novonordisk.commailto:mrz@novonordisk.commrz@novonordisk.com
Frank Daniel Mersebach
(US)
+1 609 235 8567 fdni@novonordisk.com
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Company announcement No 65 / 2014
Page 4 of 4
Novo Nordisk A/S
Investor Relations
Navo Allé
2880 Bagsvcerd
Denmark
Te leph on e:
+45 4444 8888
Inte rn et:
www. nov on ordisk.com
CVR no:
24 25 67 90
Compa ny a nn ouncement N o 65 l 2014
|
distributed by
|
